leisure time -WSS

leisure time

author：focus 2025-09-30 14:59:10 - browse：9231

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： FDA rejects Alnylam's heart disease treatment over insufficient data

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Phenylephrine and the overlooked value of the placebo effect

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Bill would stop addiction treatment from triggering child abuse inquiry

Phenylephrine and the overlooked value of the placebo effect

Feng Zhang CRISPR delivery startup lays off quarter of staff

entertainment

leisure time

focus

In Memoriam: Notable people who died in 2023

Feng Zhang, Grail founder join forces on new gene editing startup

After affirmative action ruling, medical educators look to 'holistic review'

Bristol 'take

United colonoscopy coverage change 'may cost lives,' doctors say

Burning questions for the 2024 JPM Healthcare Conference

23andMe had bad news about my health. I wish a person had delivered it

Videos point to link between seizures and unexplained toddler deaths

Medicare proposal to cover medical devices draws a mixed reaction

What to expect at HLTH 2023, the health care industry conference

entertainment

Was Amgen transparent enough on FDA's concern on cancer drug?

Was Amgen transparent enough on FDA's concern on cancer drug?

Phenylephrine and the overlooked value of the placebo effect

AI can decode, harness the power of the humane immune system

What to expect at HLTH 2023, the health care industry conference

A virus, fished out of a lake, may have saved a man’s life

Wikipedia

explore

hotspot

focus